(PSNL) – FDA
-
Myriad Genetics (MYGN) and Personalis Partner to Market Solutions to Pharma Customers
-
Personalis, (PSNL) ABRCC and Criterium Announce Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
-
-
-
-
-
Back to PSNL Stock Lookup